|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Capitanio U, Bensalah K, Bex A, Boorjian
SA, Bray F, Coleman J, Gore JL, Sun M, Wood C and Russo P:
Epidemiology of renal cell carcinoma. Eur Urol. 75:74–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Capitanio U and Montorsi F: Renal cancer.
Lancet. 387:894–906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu L, Cao Y, Chen C, Zhang X, McNabola A,
Wilkie D, Wilhelm S, Lynch M and Carter C: Sorafenib blocks the
RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor
cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer
Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ljungberg B, Albiges L, Abu-Ghanem Y,
Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F,
Hora M, Kuczyk MA, et al: European association of urology
guidelines on renal cell carcinoma: The 2019 update. Eur Urol.
75:799–810. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sano Y, Kogashiwa Y, Araki R, Enoki Y,
Ikeda T, Yoda T, Nakahira M and Sugasawa M: Correlation of
inflammatory markers, survival, and COX2 expression in oral cancer
and implications for prognosis. Otolaryngol Head Neck Surg.
158:667–676. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gurram B, Zhang S, Li M, Li H, Xie Y, Cui
H, Du J, Fan J, Wang J and Peng X: Celecoxib conjugated fluorescent
probe for identification and discrimination of cyclooxygenase-2
enzyme in cancer cells. Anal Chem. 90:5187–5193. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu WK, Sung JJ, Lee CW, Yu J and Cho CH:
Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: An
update on the molecular mechanisms. Cancer Lett. 295:7–16. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hashemi Goradel N, Najafi M, Salehi E,
Farhood B and Mortezaee K: Cyclooxygenase-2 in cancer: A review. J
Cell Physiol. 234:5683–5699. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li H, Zhu F, Boardman LA, Wang L, Oi N,
Liu K, Li X, Fu Y, Limburg PJ, Bode AM and Dong Z: Aspirin prevents
colorectal cancer by normalizing EGFR expression. EBioMedicine.
2:447–455. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiao J, Wang F, Lu H, Xu S, Zou L, Tian Q,
Fu Y, Lin X, Liu L, Yuan P, et al: Targeting the COX2/MET/TOPK
signaling axis induces apoptosis in gefitinib-resistant NSCLC
cells. Cell Death Dis. 10:7772019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tong D, Liu Q, Wang LA, Xie Q, Pang J,
Huang Y, Wang L, Liu G, Zhang D, Lan W and Jiang J: The roles of
the COX2/PGE2/EP axis in therapeutic resistance. Cancer Metastasis
Rev. 37:355–368. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Khafaga AF, Shamma RN, Abdeen A, Barakat
AM, Noreldin AE, Elzoghby AO and Sallam MA: Celecoxib repurposing
in cancer therapy: Molecular mechanisms and nanomedicine-based
delivery technologies. Nanomedicine (Lond). 16:1691–1712. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bley N, Lederer M, Pfalz B, Reinke C,
Fuchs T, Glaß M, Möller B and Hüttelmaier S: Stress granules are
dispensable for mRNA stabilization during cellular stress. Nucleic
Acids Res. 43:e262015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Protter DSW and Parker R: Principles and
properties of stress granules. Trends Cell Biol. 26:668–679. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grabocka E and Bar-Sagi D: Mutant KRAS
enhances tumor cell fitness by upregulating stress granules. Cell.
167:1803–1813.e12. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thedieck K, Holzwarth B, Prentzell MT,
Boehlke C, Kläsener K, Ruf S, Sonntag AG, Maerz L, Grellscheid SN,
Kremmer E, et al: Inhibition of mTORC1 by astrin and stress
granules prevents apoptosis in cancer cells. Cell. 154:859–874.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Somasekharan SP, El-Naggar A, Leprivier G,
Cheng H, Hajee S, Grunewald TG, Zhang F, Ng T, Delattre O,
Evdokimova V, et al: YB-1 regulates stress granule formation and
tumor progression by translationally activating G3BP1. J Cell Biol.
208:913–929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao X, Jiang L, Gong Y, Chen X, Ying M,
Zhu H, He Q, Yang B and Cao J: Stress granule: A promising target
for cancer treatment. Br J Pharmacol. 176:4421–4433. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao J, Fu X, Chen H, Min L, Sun J, Yin J,
Guo J, Li H, Tang Z, Ruan Y, et al: G3BP1 interacts with YWHAZ to
regulate chemoresistance and predict adjuvant chemotherapy benefit
in gastric cancer. Br J Cancer. 124:425–436. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shi Q, Zhu Y, Ma J, Chang K, Ding D, Bai
Y, Gao K, Zhang P, Mo R, Feng K, et al: Prostate cancer-associated
SPOP mutations enhance cancer cell survival and docetaxel
resistance by upregulating Caprin1-dependent stress granule
assembly. Mol Cancer. 18:1702019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ansari MY and Haqqi TM: Interleukin-1β
induced stress granules sequester COX-2 mRNA and regulates its
stability and translation in human OA chondrocytes. Sci Rep.
6:276112016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaminska K, Szczylik C, Lian F and
Czarnecka AM: The role of prostaglandin E2 in renal cell cancer
development: Future implications for prognosis and therapy. Future
Oncol. 10:2177–2187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong XF, Liu TQ, Zhi XT, Zou J, Zhong JT,
Li T, Mo XL, Zhou W, Guo WW, Liu X, et al: COX-2/PGE2 axis
regulates HIF2α activity to promote hepatocellular carcinoma
hypoxic response and reduce the sensitivity of sorafenib treatment.
Clin Cancer Res. 24:3204–3216. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Benech N, Walter T and Saurin JC: Desmoid
tumors and celecoxib with sorafenib. N Engl J Med. 376:2595–2597.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang P, Mathieu C, Kolaitis RM, Zhang P,
Messing J, Yurtsever U, Yang Z, Wu J, Li Y, Pan Q, et al: G3BP1 is
a tunable switch that triggers phase separation to assemble stress
granules. Cell. 181:325–345.e28. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tołoczko-Iwaniuk N, Dziemiańczyk-Pakieła
D, Nowaszewska BK, Celińska-Janowicz K and Miltyk W: Celecoxib in
cancer therapy and prevention-review. Curr Drug Targets.
20:302–315. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun Y, Dai H, Chen S, Zhang Y, Wu T, Cao
X, Zhao G, Xu A, Wang J and Wu L: Disruption of chromosomal
architecture of cox2 locus sensitizes lung cancer cells to
radiotherapy. Mol Ther. 26:2456–2465. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tong D, Liu Q, Liu G, Xu J, Lan W, Jiang
Y, Xiao H, Zhang D and Jiang J: Metformin inhibits
castration-induced EMT in prostate cancer by repressing
COX2/PGE2/STAT3 axis. Cancer Lett. 389:23–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Prima V, Kaliberova LN, Kaliberov S,
Curiel DT and Kusmartsev S: COX2/mPGES1/PGE2 pathway regulates
PD-L1 expression in tumor-associated macrophages and
myeloid-derived suppressor cells. Proc Natl Acad Sci USA.
114:1117–1122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tudor DV, Bâldea I, Lupu M, Kacso T,
Kutasi E, Hopârtean A, Stretea R and Gabriela Filip A: COX-2 as a
potential biomarker and therapeutic target in melanoma. Cancer Biol
Med. 17:20–31. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lala PK, Nandi P and Majumder M: Roles of
prostaglandins in tumor-associated lymphangiogenesis with special
reference to breast cancer. Cancer Metastasis Rev. 37:369–384.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Davies G, Salter J, Hills M, Martin LA,
Sacks N and Dowsett M: Correlation between cyclooxygenase-2
expression and angiogenesis in human breast cancer. Clin Cancer
Res. 9:2651–2656. 2003.PubMed/NCBI
|
|
34
|
Li Z, Zhang Y, Kim WJ and Daaka Y: PGE2
promotes renal carcinoma cell invasion through activated RalA.
Oncogene. 32:1408–1415. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim SH, Roszik J, Cho SN, Ogata D, Milton
DR, Peng W, Menter DG, Ekmekcioglu S and Grimm EA: The COX2
effector microsomal PGE2 synthase 1 is a regulator of
immunosuppression in cutaneous melanoma. Clin Cancer Res.
25:1650–1663. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mao Y, Poschke I, Wennerberg E, Pico de
Coaña Y, Egyhazi Brage S, Schultz I, Hansson J, Masucci G,
Lundqvist A and Kiessling R: Melanoma-educated CD14+ cells acquire
a myeloid-derived suppressor cell phenotype through COX-2-dependent
mechanisms. Cancer Res. 73:3877–3887. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang X, Zhang L, O'Neill A, Bahamon B,
Alsop DC, Mier JW, Goldberg SN, Signoretti S, Atkins MB, Wood CG
and Bhatt RS: Cox-2 inhibition enhances the activity of sunitinib
in human renal cell carcinoma xenografts. Br J Cancer. 108:319–326.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cervello M, Bachvarov D, Lampiasi N,
Cusimano A, Azzolina A, McCubrey JA and Montalto G: Novel
combination of sorafenib and celecoxib provides synergistic
anti-proliferative and pro-apoptotic effects in human liver cancer
cells. PLoS One. 8:e655692013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang H, Li Z and Wang K: Combining
sorafenib with celecoxib synergistically inhibits tumor growth of
non-small cell lung cancer cells in vitro and in
vivo. Oncol Rep. 31:1954–1960. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shi L, Xu L, Wu C, Xue B, Jin X, Yang J
and Zhu X: Celecoxib-induced self-assembly of smart
albumin-doxorubicin conjugate for enhanced cancer therapy. ACS Appl
Mater Interfaces. 10:8555–8565. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen JC, Wang JC, Pan YX, Yi MJ, Chen JB,
Wang XH, Fu YZ, Zhang YJ, Xu L, Chen MS, et al: Preventive effect
of celecoxib in sorafenib-related hand-foot syndrome in
hepatocellular carcinoma patients, a single-center, open-label,
randomized, controlled clinical phase III trial. Am J Cancer Res.
10:1467–1476. 2020.PubMed/NCBI
|
|
42
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bergers G and Hanahan D: Modes of
resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rini BI and Atkins MB: Resistance to
targeted therapy in renal-cell carcinoma. Lancet Oncol.
10:992–1000. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Fulda S, Gorman AM, Hori O and Samali A:
Cellular stress responses: Cell survival and cell death. Int J Cell
Biol. 2010:2140742010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wippich F, Bodenmiller B, Trajkovska MG,
Wanka S, Aebersold R and Pelkmans L: Dual specificity kinase DYRK3
couples stress granule condensation/dissolution to mTORC1
signaling. Cell. 152:791–805. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Arimoto K, Fukuda H, Imajoh-Ohmi S, Saito
H and Takekawa M: Formation of stress granules inhibits apoptosis
by suppressing stress-responsive MAPK pathways. Nat Cell Biol.
10:1324–1332. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Adjibade P, St-Sauveur VG, Quevillon
Huberdeau M, Fournier MJ, Savard A, Coudert L, Khandjian EW and
Mazroui R: Sorafenib, a multikinase inhibitor, induces formation of
stress granules in hepatocarcinoma cells. Oncotarget.
6:43927–43943. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang F, Li J, Fan S, Jin Z and Huang C:
Targeting stress granules: A novel therapeutic strategy for human
diseases. Pharmacol Res. 161:1051432020. View Article : Google Scholar : PubMed/NCBI
|
